Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal bupivacaine TAP block timing and MEV90 volume study in laparoscopic colorectal cancer resection
ChiCTR2600132416Phase 4Not yet recruiting
- Sponsor
- Beijing No. 6 Hospital
- Start
- Sep 2026
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of liposomal bupivacaine in postoperative pain (3 arms), sponsored by Beijing No. 6 Hospital. Primary endpoints: Determination of effective blockade (Part 1) and Postoperative quality of recovery (Part 2). Planned start Sep 2026; status: not yet recruiting.
02
Drugs
liposomal bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2600132416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132416.